Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537356 | 0.90 | CYP2C9 (0.47) | KMT2ACYP2D6CYP2C9MEN1HPGD | |
| SCHEMBL13145231 | 0.82 | CYP2C9 (0.51) | KMT2ACYP2D6CYP2C9MEN1HPGD | |
| SCHEMBL537416 | 0.73 | CYP2D6 (0.52) | KMT2ACYP2D6CYP2C9MEN1HPGD | |
| SCHEMBL537286 | 0.72 | CYP2C9 (0.54) | KMT2ACYP2D6CYP2C9MEN1HPGD | |
| SCHEMBL12833903 | 0.69 | CDK4 (0.47) | KMT2ACYP2D6CYP2C9MEN1HPGD | |
| SCHEMBL8150783 | 0.67 | CD274 (0.85) | HPGDTSHRSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12833435 | 0.66 | CDK4 (0.47) | KMT2ACYP2D6CYP2C9MEN1HPGD | |
| SCHEMBL26307601 | 0.66 | CYP2C9 (1.00) | KMT2ACYP2D6CYP2C9MEN1HPGD | |
| SCHEMBL1382764 | 0.65 | SMN1; SMN2 (0.95) | HPGDTSHRSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13380210 | 0.65 | SMN1; SMN2 (0.65) | CYP2D6CYP2C9TSHRSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410144-B2 | Substituted indolo-pyridinone compounds | ARQULE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410144-B2 | Substituted indolo-pyridinone compounds | ARQULE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410144-B2 | Substituted indolo-pyridinone compounds | ARQULE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2414344-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114896-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114896-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | MKI67, CCNI, CDK4 | KMT2A 2288/4885CYP2D6 359/4885CYP2C9 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.